Category

Cohort News

Bardy Diagnostics® Announces CE Mark Certification for 14-Day Carnation® Ambulatory Monitor (CAM®) Patch in Europe and Expansion of Home Enrollment Program Amidst COVID-19 Crisis

"CE marking of the 14-Day CAM patch is a significant corporate milestone and a testament to the quality of the CAM patch and BardyDx's compliance with all applicable European health, safety, performance and environmental requirements," said Ed Vertatschitsch, Chief Operating Officer.
Read More →

Alleviant Medical completes $6.5m offering

Congestive heart failure treatment developer Alleviant Medical filed an SEC Form D to confirm the sale of $6.5 million in an equity offering. The Austin, Texas-based company reached its total offering amount of $6.5 million after making the first sale in the new notice on May 1. It had no intention of letting the offering last longer than one year and did not make it in connection with a business transaction.
Read More →

Genetesis lands strategic investment to close $9.2M Series B

//
Categories
Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFluxTM imaging, today announced several important updates. The company has closed significant strategic investments from TDK Ventures and an undisclosed Fortune 500 global, healthcare company, completing a $9.2M Series B financing. The round included participation by return investors CincyTech, Ohio Innovation Fund and Mark Cuban.
Read More →

Medable Secures $25M Funding To Reduce Clinical Trial Timelines

“The continued participation in clinical trials is important right now,” Medable co-founder and CEO Michelle Longmire, M.D., told Crunchbase News. “Prior to COVID, decentralized clinical trials were a novel, innovative approach. Now that clinics are shut down, decentralized clinical trials are the only approach to continued clinical trials, especially for finding a COVID vaccine. We are the only tech company to be able to provide this service, and we had to make sure we had the capital to execute this platform.”
Read More →